Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective

被引：20

作者：

Cabezas-Camarero, Santiago ^{[1
]}

Perez-Segura, Pedro ^{[1
]}

机构：

[1] Hosp Clin Univ San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Madrid, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 169卷

关键词：

Head and neck cancer; Neoadjuvant therapy; Immunotherapy; Immune checkpoint inhibitors; Tumor response; Biomarkers; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; RECURRENT; NIVOLUMAB; WINDOW; TRIAL; PEMBROLIZUMAB; MULTICENTER; DURVALUMAB; BIOMARKER;

D O I：

10.1016/j.critrevonc.2021.103569

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune-checkpoint inhibitors (ICIs) have shown to improve survival in the first- and second-line settings of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). In the past two years more than a dozen neoadjuvant IO studies have been reported in SCCHN, demonstrating the feasibility of one or a few doses of single agent or combination ICIs. This approach seems safe with no surgical delays due to toxicity in most of the studies with no new safety signals. Efficacy in terms of pathologic response appears promising both with single-agent ICIs and especially with chemo-IO combinations. The scientific rationale and current clinical evidence of neoadjuvant IO trials in SCCHN will be reviewed, including currently debated aspects such as the methodology for radiological and pathological evaluation as well as types and criteria for biomarker use in this setting. Finally, the future perspective of neoadjuvant IO in SCCHN will be approached.

引用

页数：13

共 51 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2] Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches [J].

Allen, Clint T. ;

Clavijo, Paul E. ;

Van Waes, Carter ;

Chen, Zhong .

CANCERS, 2015, 7 (04) :2397-2414

[3] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[4]

Bernal MO, 2020, J CLIN ONCOL, V38

[5] Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature [J].

Bossi, Paolo ;

Alfieri, Salvatore ;

Strojan, Primoz ;

Takes, Robert P. ;

Lopez, Fernando ;

Makitie, Antti ;

Saba, Nabil F. ;

Pablo Rodrigo, Juan ;

Bradford, Carol ;

Suarez, Carlos ;

Zafereo, Mark ;

Forastiere, Arlene A. ;

Vermorken, Jan B. ;

Quer, Miquel ;

Sanabria, Alvaro ;

Simo, Ricard ;

de Bree, Remco ;

Rinaldo, Alessandra ;

Ferlito, Alfio .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 137 :84-91

[6] Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 "PembroRad" randomized trial [J].

Bourhis, J. ;

Sire, C. ;

Tao, Y. ;

Martin, L. ;

Alfonsi, M. ;

Prevost, J. B. ;

Rives, M. ;

Lafond, C. ;

Tourani, J. M. ;

Biau, J. ;

Geoffrois, L. ;

Coutte, A. ;

Liem, X. ;

Vauleon, E. ;

Drouet, F. ;

Pechery, A. ;

Guigay, J. ;

Wanneveich, M. ;

Auperin, A. ;

Sun, X. .

ANNALS OF ONCOLOGY, 2020, 31 :S1168-S1168

[7]

Bourhis J., ANN ONCOL, V32, pS1283

[8] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[9] Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer [J].

Chera, Bhishamjit S. ;

Kumar, Sunil ;

Beaty, Brian T. ;

Marron, David ;

Jefferys, Stuart ;

Green, Rebecca ;

Goldman, Emily C. ;

Amdur, Robert ;

Sheets, Nathan ;

Dagan, Roi ;

Hayes, D. Neil ;

Weiss, Jared ;

Grilley-Olson, Juneko E. ;

Zanation, Adam ;

Hackman, Trevor ;

Blumberg, Jeffrey M. ;

Patel, Samip ;

Weissler, Mark ;

Tan, Xianming M. ;

Parker, Joel S. ;

Mendenhall, William ;

Gupta, Gaorav P. .

CLINICAL CANCER RESEARCH, 2019, 25 (15) :4682-4690

[10] Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) [J].

Cohen, E. E. ;

Ferris, R. L. ;

Psyrri, A. ;

Haddad, R. ;

Tahara, M. ;

Bourhis, J. ;

Harrington, K. J. ;

Chang, P. M-H. ;

Lin, J-C. ;

Razaq, M. ;

Teixeira, M. M. ;

Lovey, J. ;

Chamois, J. ;

Rueda Dominguez, A. ;

Hu, C. ;

Dvorkin, M. ;

De Beukelaer, S. ;

Pavlov, D. ;

Thurm, H. ;

Lee, N. .

ANNALS OF ONCOLOGY, 2020, 31 :S658-S658

← 1 2 3 4 5 6 →